In a welcome move, AtriCure saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating in the early stages of their moves. See if AtriCure can continue to show renewed price strength and hit that benchmark.
AtriCure is building a cup with handle with a 38.33 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
The company showed 0% EPS growth last quarter, while sales growth came in at 17%.
AtriCure holds the No. 7 rank among its peers in the Medical-Systems/Equipment industry group. Brainsway ADR, iRadimed and IDEXX Laboratories are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
